According to Zhitong Finance App News, Zhongheng Group (600252.SH) disclosed its 2023 annual report. The company achieved revenue of 3,097 billion yuan in 2023, up 14.1% year on year; net profit to mother was 84.31 million yuan, up 6.69% year on year; after deducting non-net profit of 22.73 million yuan, up 321.59% year on year; basic earnings per share were 0.0246 yuan. The company plans to distribute a cash dividend of 0.1 yuan (tax included) for every 10 shares to all shareholders.

Net profit attributable to shareholders of listed companies increased 321.59% year on year, and basic earnings per share after deducting non-recurring profit and loss increased 321.50% year on year. The main reason was to seize the 2022 national health insurance catalogue adjustment opportunity to complete the relief of indications. In March 2023, the scope of payment for injectable thrombotron (freeze-dried) medical insurance returned to the scope of drug instructions, broadened the department use of medication in medical institutions. The company also carried out refined operations under enhanced channel automatic control, stabilized sales teams, and marketers actively carried out business to enable the cardiovascular and cerebrovascular sector to sell drugs. There was an increase in gross profit; the second was due to an increase in interest income from the company's current deposit and a year-on-year decline in credit impairment losses on other accounts receivable.